Association of pretreatment neutrophil‐to‐lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration‐resistant prostate cancer (mCRPC) treated with first‐line docetaxel. (14th February 2014)

• Record Type: Journal Article
• Authors: Nuhn, Philipp; Vaghasia, Ajay M.; Goyal, Jatinder; Zhou, Xian C.; Carducci, Michael A.; Eisenberger, Mario A.; Antonarakis, Emmanuel S.
• Is Part Of: BJU international. Volume 114:Number 6B(2014)
• Page Start: E11
• Page End: E17
• Publication Date: 2014-02-14
• Subjects: Genitourinary organs -- Diseases -- Periodicals; Genitourinary organs -- Surgery -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1111/bju.12531
• Languages: English
• ISSNs: 1464-4096

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bju12531-sec-0001" sec-type="section"> <title>Objective</title> <p> <list id="bju12531-list-0001" list-type="bullet"> <list-item> <p>To determine whether the pretreatment neutrophil‐to‐lymphocyte ratio (NLR), a measure of systemic inflammatory response, is associated with overall survival (OS) in men receiving chemotherapy with docetaxel for metastatic castration‐resistant prostate cancer (mCRPC).</p> </list-item> </list> </p> </sec> <sec id="bju12531-sec-0002" sec-type="section"> <title>Patients and Methods</title> <p> <list id="bju12531-list-0002" list-type="bullet"> <list-item> <p>Records from 238 consecutive patients who were treated with first‐line docetaxel‐containing chemotherapy for mCRPC at a single high‐volume centre from 1998 to 2010 (and who had adequate information to enable calculation of NLR) were reviewed.</p> </list-item> <list-item> <p>Univariable and multivariable Cox regression models were used to predict OS after chemotherapy initiation.</p> </list-item> </list> </p> </sec> <sec id="bju12531-sec-0003" sec-type="section"> <title>Results</title> <p> <list id="bju12531-list-0003" list-type="bullet"> <list-item> <p>In univariable analyses, the NLR as a discrete variable (optimal threshold 3.0) was significantly associated with OS (<italic>P</italic> = 0.001).</p> </list-item> <list-item> <p>In multivariable analyses, a lower NLR (≤3.0) was associated with lower risk of all‐cause mortality (<italic>P</italic> = 0.002).</p> </list-item> <list-item> <p>In Kaplan–Meier analysis, the median OS was higher (18.3 vs 14.4 months) in patients that did not have an elevated NLR than in those with an elevated NLR (log‐rank; <italic>P</italic> < 0.001).</p> </list-item> </list> </p> </sec> <sec id="bju12531-sec-0004" sec-type="section"> <title>Conclusions</title> <p> <list id="bju12531-list-0004" list-type="bullet"> <list-item> <p>Men who were treated with first‐line docetaxel for mCRPC who had a low pretreatment NLR (≤3.0) had significantly longer OS.</p> </list-item> <list-item> <p>NLR may be a potentially useful clinical marker of systemic inflammatory response in predicting OS in men with mCRPC who receive docetaxel and may be helpful to stratify patients for clinical trials.</p> </list-item> <list-item> <p>These findings derived from a retrospective analysis need to be validated in larger populations in prospective studies, and in the context of different therapies.</p> </list-item> </list> </p> </sec> </abstract>